Prevalence of abnormal serum vitamin D, PTH, calcium, and phosphorus in patients with chronic kidney disease: results of the study to evaluate early kidney disease  by Rouached, Mervet et al.
Vitamin D levels and early
mortality among incident
hemodialysis patients
Kidney International (2008) 74, 389; doi:10.1038/ki.2008.168
To the Editor: We greatly appreciate the large study of Wolf
et al.1 pointing a link between low serum 25-OH vitamin D
levels and early mortality among incident hemodialysis
patients who did not beneficiate of active vitamin D.
The inverse link between higher all-cause mortality and
lower 25-OH vitamin D levels in these patients strongly
suggests that vitamin D deficiency is a mortality risk factor
that may be reversed by its correction. Unfortunately, the fact
that the patients who eventually received 1aOH vitamin D
were previously better treated (with higher arteriovenous
fistula prevalence and at lower risk (lower heart failure
prevalence)) skews the evidence that the survival benefit was
only due to active vitamin D administration. Therefore, it is
interesting to recall that the risk of cancer was significantly
reduced by native vitamin D increasing serum 25-OH
vitamin D above 80 nmol/l (by a placebo-controlled rando-
mized trial performed in post-menopausal patients in whom
50 cases of new cancer was observed).2 Therefore, we suggest
that newer 1aOH vitamin D derivatives survival benefit
should be proven by a placebo-controlled trial in patients
with 25-OH vitamin D levels X70 nmol/l as recommended
by the National Kidney Foundation-Kidney Disease Out-
comes Quality Initiative (NKF-K/DOQI) for the CKD grades
3–4 patients.
1. Wolf M, Shah A, Gutierrez O et al. Vitamin D levels and early mortality
among incident hemodialysis patients. Kidney Int 2007; 72: 1004–1013.
2. Lappe JM, Travers-Gustafson D, Davies KM et al. Vitamin D and calcium
supplementation reduces cancer risk: results of a randomized trial.
Am J Clin Nutr 2007; 85: 1586–1591.
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We thank the authors for their comments regarding
deficiency of 25-hydroxyvitamin D (25D) as a novel risk
factor for mortality.1 Although we attempted to adjust for
baseline factors at the initiation of dialysis including
certain quality of care indicators such as fistula prevalence,
we agree with the authors that residual confounding
remains a limitation in this and other observational
studies. We also agree with the authors that the benefits
of maintaining normal 25D levels observed in other
clinical settings such as cancer prevention lend further
evidence in support of the importance of the vitamin D
axis in health.
We do recommend caution, however, when attempting
to infer the relative importance of 25D versus calcitriol
(1,25D) deficiency based on our study. Although it is
tempting to conclude that 25D deficiency is more
important than 1,25D deficiency given that the greatest
risk of mortality was observed in the group with the lowest
25D levels, it is important to recognize that virtually all
patients in this study were profoundly 1,25D deficient.
Thus, the group of patients with severe 25D deficiency also
had severe 1,25D deficiency: they were globally deficient in
the vitamin D axis.
Although we strongly agree with the suggestion that
randomized controlled trials are needed to test the benefits
of active vitamin D preparations on survival in patients
with kidney disease, we also believe that trials are needed
to test the effects of correction of 25D deficiency either
alone or in combination with active vitamin D.
1. Wolf M, Shah A, Gutierrez O et al. Vitamin D levels and early mortality
among incident hemodialysis patients. Kidney Int 2007; 72: 1004–1013.
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To the Editor: Levin et al.1 have documented that serum
calcitriol decrease with glomerular filtration rate decline is
independent of calcidiol. As low calcitriol is associated with
coronary calcification, they speculate that hypocalcitriolemia
favors vascular calcification and hyperparathyroidism, and
propose to perform randomized trial with activated vitamin
D against placebo, but not against ergocalciferol, because,
according to their citation of our cohort study,2 vitamin D2
would not effectively suppress parathyroid hormone.
http://www.kidney-international.org l e t t e r t o t h e e d i t o r
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In this study, we have actually used calcidiol, which
increased serum 25 OH vitamin D levels from 10 to 30 ng/ml
and those of calcitriol from 84 to 100 pmol/L. In addition
1.2 g/day of elemental calcium was given as CaCO3 for
phosphate binding. C-terminal parathyroid hormone levels
stabilized for 18 months in spite of a glomerular filtration
rate decline from 25 to 15 ml/min, suggesting a decrease
in parathyroid hormone secretion. Hyperparathyroidism
suppression was furthermore evidenced by a decrease of
alkaline phosphatase and bone remodeling parameters.
Meanwhile, two cohort studies of 40 young adults with
childhood-onset end-stage renal disease have been reported,
which documented a coronary calcification prevalence of
92% in Heidelberg and 10% in Berlin, although biographical
and therapeutical characteristics were comparable at the
exception of vitamin D therapy that was based in Heidelberg
mainly on 1aOH vitamin D (eightfolds greater yearly dose),
whereas in Berlin, it was based on 5750 IU/day of vitamin D3,
a dose which according to Garabedian yielded approximately
60 ng/ml of serum calcidiol.3
Therefore, we would like to propose that in predialysis
as in dialysis patients, activated vitamin D be evaluated against
placebo provided plain or 25 OH vitamin D3 has first stabi-
lized their 25 OH vitamin D serum levels at 40±10 ng/ml.
1. Levin A, Bakris GL, Molitch M et al. Prevalence of abnormal serum
vitamin D, PTH, calcium, and phosphorus in patients with chronic kidney
disease: results of the study to evaluate early kidney disease. Kidney Int
2007; 71: 31–38.
2. Fournier A, Idrissi A, Sebert JL et al. Preventing renal bone disease in
moderate renal failure with CaCO3 and 25(OH) vitamin D3. Kidney Int
Suppl 1988; 24: S178–S179.
3. Fournier A, Harbouche L, Mansour J et al. Impact of calcium and
vitamin D therapy on arterial and cardiac disease in young adults with
childhood-onset end stage renal disease. Nephrol Dial Transplant 2007;
22: 956–957; author reply 957–958.
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To the Editor: We read Verzola et al.’s1 article with great
interest. The authors have pointed out the significance of
glomerular cell injury and a correlation between the renal
microvascular injury and the magnitude of tubulointerstitial
fibrosis in type II diabetic nephropathy. Such correlation is
further supported by recent intrarenal hemodynamic study,
which reveals a phenomenon the so-called hemodynamic
maladjustment secondary to glomerular endothelial cell
dysfunction, which is characterized by a preferential con-
striction of the efferent arteriole, and a subsequent reduction
in peritubular capillary flow inducing a chronic ischemic
injury to the tubulointerstitium.2 The peritubular capillary
flow reduction correlates inversely with the magnitude of
tubulointerstitial fibrosis, and it progressively decreases as the
disease severity increases from normoalbuminuric to albu-
minuric type II diabetic nephropathy. Thus, renal micro-
vascular injury has a significant impact on renal disease
progression. In this regard, it is mandatory to recognize renal
microvascular disease at an early stage of type II diabetic
nephropathy in which the mechanism of vascular repair is
still adequately maintained,3 and treatment at this early stage
under favourable environment is capable of restoring renal
perfusion and function.4 To accomplish an effective pre-
ventive strategy of renal disease progression in type II diabetic
nephropathy, it would require a more sensitive diagnostic
marker than microalbuminuria, such as fractional excretion
of magnesium, to screen early stage of diabetic nephropathy.5
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We thank Drs Narisa and Prasit Futrakul for their interest
in our paper.1 The findings observed in their studies,
implying a maladaptive constriction of the efferent
arteriole and downstream vascular and tubulointerstitial
damage in type II diabetic patients, are appealing.2 One
of the basic abnormalities in diabetic nephropathy is
microalbuminuria, which eventually progresses to protein-
uria. Downstream into the tubular compartment, the
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